Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Annual Meeting scheduled for September 24, 2026, with a focus on electing six independent directors and advancing clinical priorities.

• Board highlights recent stabilization, leadership changes, and a sharpened clinical focus, especially on blarcamesine's core indications.

• Recent FDA engagement includes a meeting to discuss pediatric inclusion in a Phase 3 Rett Syndrome study.

• Board claims a solid cash position and no long-term debt, supporting focused clinical and regulatory strategies.

• Forward-looking statements caution about risks and uncertainties, referencing recent SEC filings for further details.

Voting matters and shareholder proposals

• Shareholders are urged to vote for the Board’s six nominees using the WHITE proxy card.

• Competing slate from PVG criticized for lack of relevant experience and potential conflicts of interest.

• Board asserts PVG’s plan would reverse recent progress and risk shareholder value.

Board of directors and corporate governance

• All current Board members standing for election are independent, with half the Board refreshed since early 2026.

• Two new independent nominees, Gautam Patel and Dr. Adrian Senderowicz, bring significant life sciences and regulatory experience.

• Detailed comparison provided between Board and PVG nominees, emphasizing relevant experience and independence.